NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Phio Pharmaceuticals Corp. (PHIO) Stock Analysis

Phio Pharmaceuticals Corp. (PHIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PHIO

$0.89

+$0.00 (+0.31%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PHIO with… →

PHIO Key Statistics

As of Oct 21, 2026
Trading
Open
$0.91
Previous Close
$0.89
Day's Range
0.86–0.92
52-Week Range
0.81–4.19
Volume
99.05K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.84
Valuation
Market Cap
$10.40M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.29
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.70M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.62M
1-Year Return
−57.99%
Dividend and dates
Avg Volume
135.68K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PHIO closed at $0.89, −57.99% over 1 year.

Phio Pharmaceuticals Corp. (PHIO) has a market capitalization of $10.40M.

In fiscal 2025, PHIO reported revenue of $0.00.

PHIO Stock Return by Calendar Year

Phio Pharmaceuticals Corp. (PHIO) 10-year return: what $10,000 became

1 year
$10,000 $4,201
−57.99%
5 years
$10,000 $48
−99.52%
10 years
$10,000 $0.13
−99.999%

If you had invested $10,000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, at the close on October 21, 2016, it would have been worth $0.13 at the close on October 21, 2026: −99.999% in total, −67.62% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−14.77%
2025−41.67%
2024−73.68%
2023−82.97%
2022−62.80%
2021−62.83%
2020−71.40%
2019−48.18%
2018−94.06%
2017−22.24%
2016 (partial year)−70.58%

As of October 21, 2026.

PHIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.70M—
2024$0.00−$7.15M—
2023$0.00−$10.83M—
2022$0.00−$11.48M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$9.22M−$8.70M—
2024$0.00—−$7.39M−$7.15M—
2023$0.00—−$10.70M−$10.83M—
2022$0.00—−$11.46M−$11.48M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Phio Pharmaceuticals Corp. (PHIO) carries a market capitalisation of $10.40M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 6.

PHIO last closed at $0.89 on October 21, 2026. That is $0.00 (+0.31%) against the previous close. Over the past 52 weeks the price has ranged from $0.81 to $4.19. The latest close sits 10.07% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $8.70M. Earnings per share on a trailing basis come to −1.29.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.84. Annualized volatility over the trailing 10 years is 149.76%. The trailing one-year total return is −57.99%. Measured over 10 years, that is −67.62% a year compounded.

Growth & Income

The record shows no dividend for PHIO.

So far in 2026 the total return is −14.77%. The strongest complete calendar year on file is 2017 at −22.24%; the weakest is 2018 at −94.06%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Phio Pharmaceuticals Corp. (PHIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Phio Pharmaceuticals Corp. PHIO $10.40M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Phio Pharmaceuticals Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Visit website →